Merck & Co. Eyes Neuroscience Advancement With US FDA’s New Receptivity To Biomarkers

 
• By Brenda Sandburg
Neuroscience
Merck & Co. notes changing regulatory landscape on use of biomarkers in neuroscience drug development • Source: Alamy

More from Clinical Trials

More from R&D